Experiences with recombinant FVIIa in the emergency treatment of patients with autoimmune thrombocytopenia: a review of the literature

Salama, A.; Rieke, M.; Kiesewetter, H.; Depka, M.; von Depka, M
January 2009
Annals of Hematology;Jan2009, Vol. 88 Issue 1, p11
Academic Journal
journal article
Patients with severe and refractory autoimmune thrombocytopenia (ITP) have significant morbidity and mortality rates. Currently, high-dose methylprednisolone and/or high-dose IVIgG are recommended for the emergency treatment of such patients with uncontrolled bleeding. However, some patients do not immediately respond to these therapeutic regimes and may require additional treatment. Recombinant activated FVIIa (rFVIIa) is a prothrombotic agent that appears to be useful in the treatment of patients with life-threatening bleeding. It has also been used in the treatment of several patients with thrombocytopenia. We administered rFVIIa into a patient with refractory ITP and performed a systemic review of all published reports to assess the available evidence on the efficacy and safety of this drug in patients with ITP. The results indicate that rFVIIa may help in the emergency treatment of patients with ITP who do not respond to other therapies.


Related Articles

  • Platelet production rate predicts the response to prednisone therapy in patients with idiopathic thrombocytopenic purpura. Houwerzijl, Ewout J.; Louwes, Henk; Sluiter, Wim J.; Smit, Jan W.; Vellenga, Edo; de Wolf, Joost Th. M. // Annals of Hematology;Dec2008, Vol. 87 Issue 12, p975 

    The predictive value of clinical and platelet kinetic parameters for treatment outcome in idiopathic thrombocytopenic purpura (ITP) was investigated in 75 patients with platelets ≤20 × 109/L. The platelet kinetic studies showed that the platelet production rate (PPR) was decreased...

  • Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia. Kühne, Thomas; Imbach, Paul; Kühne, Thomas // Annals of Hematology;Jul2010, Vol. 89, p67 

    Immune thrombocytopenia (ITP) is characterised by a transient or persistent decrease in platelets accompanied by an increased risk of bleeding, which can have a significant negative impact on patients' health-related quality of life. The condition has long been associated with an increased rate...

  • Evaluating bleeding severity in immune thrombocytopenia (ITP). Neunert, Cindy E. // Annals of Hematology;Jul2010, Vol. 89, p47 

    Despite immune thrombocytopenia (ITP) being one of the most common conditions encountered by the pediatric hematologist, relatively few prospective investigations of ITP exist, and treatment approaches remain highly variable. The ideal prospective clinical trial would use a reduction in severe...

  • Thrombocytopenic Purpura. Vohr, Hans-Werner // Encyclopedic Reference of Immunotoxicology;2005, p638 

    An encyclopedia entry for thrombocytopenic purpura is presented. It is a rare autoimmune disorder characterized by a shortage of platelets. This leads to bruising and spontaneous bleeding. Most of the cases are idiopathic while others are caused by drugs, infections or autoimmune disorders such...

  • Consensus Paper-ICIS Expert Meeting Basel 2009 treatment milestones in immune thrombocytopenia. Tamary, Hannah; Roganovic, Jelena; Chitlur, Meera; Nugent, Diane; Nugent, Diane J // Annals of Hematology;Jul2010, Vol. 89, p5 

    The rarity of severe complications of this disease in children makes randomized clinical trials in immune thrombocytopenia (ITP) unfeasible. Therefore, the current management recommendations for ITP are largely dependent on clinical expertise and observations. As part of its discussions during...

  • Future research in ITP: an ICIS consensus. Zehnder, James L.; Semple, John W.; Imbach, Paul; Neufeld, Ellis J.; Buchanan, George R.; Cines, Douglas B.; ICIS Study Group on Future Research in ITP // Annals of Hematology;Jul2010, Vol. 89, p19 

    While much has been learned about the basic immunology and clinical characteristics of immune thrombocytopenia, many important questions remain with regard to pathogenesis, disease progression, identification of novel therapeutic targets and approaches, and clinical trials that rationalize and...

  • Moving towards a new era in the management of chronic immune thrombocytopenia. Wadenvik, Hans; Olsson, Bob // Annals of Hematology;Jul2010, Vol. 89, p87 

    Immune thrombocytopenia (ITP) is an organ-specific autoimmune disease in which a low concentration of plasma thrombopoietin (TPO) contributes to the thrombocytopenia. Functional thrombopoietin deficiency in response to thrombocytopenia is central to the pathophysiology of chronic ITP. Decreased...

  • Hidden maternal autoimmune thrombocytopenia complicated by fetal subdural hematoma-case report and review of the literature. Rios, Lívia; Araujo Júnior, Edward; Nardozza, Luciano; Haratz, Karina; Moron, Antonio; Martins, Marília // Child's Nervous System;Jul2012, Vol. 28 Issue 7, p1113 

    The article presents case study of having subdural hematoma related to fetal autoimmune thrombocytopenia. It has been informed that a 35-year-old primigravida was referred for routine scan at 34 gestational weeks (GW) and a full-term boy was delivered by cesarean section at 39 GW with a...

  • Successful treatment with intravenous immunoglobulin of severe thrombocytopenia complicated in primary Sjögren's syndrome. Choung, Bum-Su; Yoo, Wan-Hee // Rheumatology International;May2012, Vol. 32 Issue 5, p1353 

    Sjogren's syndrome (SS) is a systemic autoimmune disease characterized by xerophthalmia, xerostomia and extraglandular manifestations. Anemia, leukopenia, thrombocytopenia and lymphoproliferative disorders, including lymphoma are well-known extraglandular, hematological complications of SS. We...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics